Penile Injection for Erectile Dysfunction: Tips and tricks | Learn how with Dr. Robert Chan
Leo's Protocol for Rock Hard Erections
Phosphodiesterases (PDE) | Role and types
Erectile Dysfunction in Prostate Cancer - Dr. Mohit Khera, 2016 Mid-Year Update
Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is known by the trademark names Stendra and Spedra. It was invented at Mitsubishi Tanabe Pharma, formerly known as Tanabe Seiyaku Co. It was then out-licensed to, and developed by, Vivus Inc. In July 2013 Vivus announced partnership with Menarini Group, which will commercialise and promote Spedra in over 40 European countries plus Australia and New Zealand. On Oct. 3, 2016 Vivus announced it had sold the exclusive rights to Avanafil in USA to Metuchen Pharmaceuticals LLC of New Jersey for an upfront payment of US$70,000,000.